Vectura joins the 'smart inhaler' party with Propeller partnership | Fierce Pharma
VECTURA SIGNS GLOBAL AGREEMENT WITH HIKMA TO DEVELOP GENERIC VERSIONS OF GSK'S ELLIPTA® PORTFOLIO
Assessing New Technologies in Aerosol Medicine: Strengths and Limitations | Respiratory Care
Vectura earns $11m milestone with Hikma generic launch
Vectura agrees $1.4bn takeover by private equity group Carlyle | pharmaphorum
Drug Delivery to the Lungs 20
Propeller Health, Vectura ink collaborative connected-inhaler deal - MassDevice
GSK ex-CFO swoops for Advair generics-maker Vectura in £958M Carlyle bid | S&P Global Market Intelligence
Philip Morris takeover of Vectura denounced by COPD Foundation
Inhalers listed in the Vectura accounts as generating revenue, or... | Download Scientific Diagram
Inhaled Product Development for Inhalers, Nebulisers & Nasal Sprays - Vectura
Vectura wins additional $10m patent damages against GSK
Track Record - Vectura
Adapting Inhaled Medication Practice in COPD and Asthma to Avoid Funding the Tobacco Industry. - Document - Gale Academic OneFile
Hikma Pharmaceuticals and Vectura codevelopment and commercialization of GSK's Breo Ellipta generics • NCK Pharma
Articles about Vectura Group plc
Hikma Pharmaceuticals PLC and Vectura Group PLC to develop generic version of GlaxoSmithKline PLC's blockbuster Ellipta inhaler
Vectura, Hikma team up to develop generic versions of GSK's Ellipta
Hikma and Vectura to Produce Generic Versions of GSK's Ellipta Meds - Pharmaceutical Processing World
Vectura, Sandoz gets favourable ruling in inhaler packaging case against GSK | Euronews
Court denies GSK appeal in Vectura intellectual property dispute - Sharecast.com
Vectura names Will Downie as new CEO
Vectura to merge with SkyePharma in £441m deal - PMLiVE
Vectura takes £40 million hit as asthma drug fails trial | pharmaphorum
